bezlotoxumab
Sign in to saveBezlotoxumab, sold under the brand name Zinplava, is a human monoclonal antibody designed for the prevention of recurrence of Clostridioides difficile infections. Bezlotoxumab binds to Clostridioides difficile toxin B.
Key facts
- Drug.H
- 9974
- Drug.type
- mab
- Drug.mab_type
- mab
- Drug.source
- u
- Drug.target
- Clostridioides difficile toxin B
- Drug.tradename
- Zinplava
- Drug.MedlinePlus
- a617003
- Drug.DailyMedID
- Bezlotoxumab
- Drug.pregnancy_AU
- B2
- Drug.routes_of_administration
- Intravenous
- Drug.ATC_prefix
- J06
- Drug.ATC_suffix
- BC03
- Drug.legal_AU
- S4
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.CAS_number
- 1246264-45-8
- Drug.DrugBank
- DB13140
via Wikipedia infobox
Wikidata facts
- Subclass of
- chemical compound
- Has use
- medication
Show 1 more fact
- subject has role
- monoclonal antibody
via Wikidata · CC0
~4 min read
Encyclopedic overview
4 sectionsContents
- Medical uses
- Mechanism of TcdB neutralization
- History
- References
Bezlotoxumab, sold under the brand name Zinplava, is a human monoclonal antibody designed for the prevention of recurrence of Clostridioides difficile infections. Bezlotoxumab binds to Clostridioides difficile toxin B.
== Medical uses == Bezlotoxumab is indicated to reduce recurrence of Clostridioides difficile infection in people who are receiving antibacterial drug treatment for Clostridioides difficile infection and are at a high risk for Clostridioides difficile infection recurrence.
Excerpted from Wikipedia’s “bezlotoxumab” article, available under the CC BY-SA 4.0 licence.